Specifically, genomic profiling based on clinical-grade NGS could identify whether PTEN loss or other GAs activating the mTOR pathway are present alongside the BRAF fusion in a pilocytic astrocytoma of patient, thus suggesting a potential responsiveness to combined sorafenib/mTOR targeted therapy. The gene discussed is BRAF; the disease is pilocytic astrocytoma.